Cost–effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients

References

• Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest108(Suppl. 4), S312–S334 (1995).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125(1), 1–7 (1996).
   PubMed Web of Science ®Google Scholar
• Stein PD, Firth J. Deep venous thrombosis and pulmonary embolism. Oxford Textbook of Medicine 4th Edition. Oxford University Press, Oxford, UK (2003).
   Google Scholar
• Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch. Intern. Med. 164(1), 17–26 (2004).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 345(18), 1298–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 163(11), 1337–1342 (2003).
   PubMed Web of Science ®Google Scholar
• Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med. Care 31(5), 403–418 (1993).
   PubMed Web of Science ®Google Scholar
• Sendi PP, Bucher HC, Harr T et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS13(9), 1115–1122 (1999).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358(9275), 9–15 (2001).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359(9319), 1715–1720 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359(9319), 1721–1726 (2002).
   PubMed Web of Science ®Google Scholar
• Gordois A, Posnett J, Borris L et al. The cost–effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J. Thromb. Haemost. 1(10), 2167–2174 (2003).
   PubMed Web of Science ®Google Scholar
• White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch. Intern. Med. 158(14), 1525–1531 (1998).
   PubMed Web of Science ®Google Scholar
• Colwell CW Jr, Collis DK, Paulson R et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J. Bone Joint Surg. Am. 81(7), 932–940 (1999).
   PubMed Web of Science ®Google Scholar
• Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch. Intern. Med. 158(8), 873–878 (1998).
   PubMed Web of Science ®Google Scholar
• Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br. J. Surg. 81(12), 1742–1746 (1994).
   PubMed Web of Science ®Google Scholar
• O’Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can. Med. Assoc. J. 150(7), 1083–1890 (1994).
   PubMed Web of Science ®Google Scholar
• Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch. Intern. Med. 160(6), 769–774 (2000).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Turkstra F, Buller HR, MacKinnon B, Magier D, Hirsh J. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch. Intern. Med. 160(5), 669–672 (2000).
   PubMed Web of Science ®Google Scholar
• Siragusa S, Beltrametti C, Barone M, Piovella F. Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombosis. Results of a transverse epidemiologic study. Minerva Cardioangiol. 45(3), 57–66 (1997).
   PubMedGoogle Scholar
• Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 132(11), 853–861 (2000).
   PubMed Web of Science ®Google Scholar
• Pellegrini VD, Jr, Clement D, Lush-Ehmann C, Keller GS, Evarts CM. The John Charnley Award. Natural history of thromboembolic disease after total hip arthroplasty. Clin. Orthop. Relat. Res. (333), 27–40 (1996).
   PubMed Web of Science ®Google Scholar
• Todd CJ, Freeman CJ, Camilleri-Ferrante C et al. Differences in mortality after fracture of hip: the east Anglian audit. Br. Med. J. 310(6984), 904–948 (1995).
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J. Am. Geriatr. Soc. 51(3), 364–370 (2003).
   PubMed Web of Science ®Google Scholar
• APDRG version 4.1. Institut für Gesundheit und Oekonomie. 12 Sept (2003).
   Google Scholar
• Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur. J. Health Econ. 4(4), 254–262 (2003).
   PubMedGoogle Scholar
• Perone N, Bounameaux H, Perrier A. Comparison of four strategies for diagnosing deep vein thrombosis: a cost–effectiveness analysis. Am. J. Med. 110(1), 33–40 (2001).
   PubMed Web of Science ®Google Scholar
• Tarmed Version 1.1r deutsch. Zentralstelle für Medizinaltarife. UVG (2002).
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 6(1), 9–17 (2003).
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Jänsson B. Cost–effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health, 2(4), 288–294 (1999).
   PubMedGoogle Scholar
• Friedman RJ. Extended thromboprophylaxis after hip or knee replacement. Orthopedics26(Suppl. 2), S225–S230 (2003).
   Google Scholar
• Bergqvist D, Benoni G, Bjorgell O et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N. Engl. J. Med. 335(10), 696–700 (1996).
   PubMed Web of Science ®Google Scholar
• Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet 362(9383), 504–505 (2003).
   PubMed Web of Science ®Google Scholar
• Bounameaux H. Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. Lancet 362(9395), 1581 (2003).
   PubMedGoogle Scholar
• Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty – a meta-analysis. Thromb. Haemost. 85(5), 940–941 (2001).
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Stein PD et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann. Intern. Med. 135(10), 858–869 (2001).
   PubMed Web of Science ®Google Scholar
• Spahn G. Compliance with self-administration of heparin injections in outpatients. Eur. J. Trauma 28(2), 104–109 (2002).
   Google Scholar
• Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch. Intern. Med. 158(18), 2001–2003 (1998).
   PubMedGoogle Scholar
• Kahn SR, Kearon C, Julian JA et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J. Thromb. Haemost. 3(4), 718–723 (2005).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(Suppl. 3), 338S–400S (2004).
   PubMed Web of Science ®Google Scholar